Clinical psychopharmacology is a specialized field within psychiatry that focuses on the study and application of medications for treating mental health disorders. Psychopharmacologists, often psychiatrists or pharmacologists, work to understand how various drugs interact with the brain and nervous system to alleviate symptoms of psychiatric conditions. They conduct research to investigate the safety and efficacy of different medications and develop guidelines for their use in clinical practice. By staying abreast of the latest advancements in pharmacology and neuroscience, clinical psychopharmacologists strive to optimize treatment outcomes and minimize adverse effects for patients.
In clinical settings, psychopharmacologists collaborate with other mental health professionals to provide comprehensive care to individuals with psychiatric disorders. They conduct thorough assessments to determine the most appropriate medication regimen based on factors such as the patient's diagnosis, symptom severity, medical history, and treatment preferences. Psychopharmacologists monitor patients' responses to medication over time, adjusting dosages or switching medications as needed to achieve optimal therapeutic effects while minimizing side effects. Through their expertise in psychopharmacology, these specialists play a vital role in improving the quality of life for individuals living with mental illness.
Title : Tailoring biblio-poetry therapies using AI and biofeedback for addiction treatment
Nile Stanley, University of North Florida, United States
Title : The A-B-C of happiness coaching
Alphonsus Obayuwana, Triple-H Project LLC, United States
Title : Clinical pharmacology of marijuana: Update 2024
Frederick J Goldstein, Philadelphia College of Osteopathic Medicine, United States
Title : Trait-based recovery: Evidence-based trait activation to reduce depression, anxiety, and improve client engagement in addiction treatment
Jason Glenn Roop, The Center for Trait-Based Transformation, United States
Title : An investigation of the factors responsible for ubstance abuse from a cognitive perspective based on a mixed method approach
Adewole Olukorede, Literary Edifice, Italy
Title : A Long-Acting Naltrexone Implant (for Opioid Use Disorder: First-in-Human Phase I Trial)
Steven M Cohen, Akyso Therapeutics, United States